Bluejay Diagnostics (BJDX) Change in Accured Expenses (2021 - 2026)
Bluejay Diagnostics (BJDX) reported Change in Accured Expenses of $268478.0 for Q1 2026, up 143.43% on a YoY basis from $110290.0 in Q1 2025, and up 354.27% sequentially from -$105588.0 in Q4 2025.
Bluejay Diagnostics (BJDX) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Bluejay Diagnostics (BJDX) has 6 years of Change in Accured Expenses data on file, last reported at $268478.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 143.43% year-over-year to $268478.0; the trailing twelve-month figure through Mar 2026 stood at $309106.0 (up 157.23% YoY), and the FY2025 full-year result was $150918.0, up 121.69% from the prior year.
- Change in Accured Expenses climbed to $268478.0 in Q1 2026, from -$105588.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $487141.0 in Q2 2023 to a low of -$967215.0 in Q4 2023.
- A 5-year average of $1769.6 and a median of $105223.0 in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses surged 1213.97% in 2022 and slumped 752.48% in 2023, its largest moves.
- Tracing BJDX's Change in Accured Expenses over 5 years: stood at -$113459.0 in 2022, then slumped by 752.48% to -$967215.0 in 2023, then surged by 90.84% to -$88561.0 in 2024, then fell by 19.23% to -$105588.0 in 2025, then soared by 354.27% to $268478.0 in 2026.
- Business Quant data shows BJDX's Change in Accured Expenses at $268478.0 in Q1 2026, -$105588.0 in Q4 2025, and $33119.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.40 Bn | 176.11 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.93 Bn | 126.05 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 108.35 Bn | 99.13 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 68.71 Bn | 67.25 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.68 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | 145.10 Mn |
| 7 | GE HealthCare Technologies | 28.04 Bn | 25.76 Bn | 1.98 Bn | -250.00 Mn |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 21.07 Mn |
| 10 | Bluejay Diagnostics | 1.06 Mn | 1.06 Mn | - | 268,478.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 268,478.00 |
| Mar 31, 2026 | 268,478.00 |
| Dec 31, 2025 | -105,588.00 |
| Dec 31, 2025 | -105,588.00 |
| Sep 30, 2025 | 33,119.00 |
| Sep 30, 2025 | 33,119.00 |
| Jun 30, 2025 | 113,097.00 |
| Jun 30, 2025 | 113,097.00 |
| Mar 31, 2025 | 110,290.00 |
| Mar 31, 2025 | 110,290.00 |
| Dec 31, 2024 | -88,561.00 |
| Dec 31, 2024 | -88,561.00 |
| Sep 30, 2024 | -707,367.00 |
| Sep 30, 2024 | -707,367.00 |
| Jun 30, 2024 | 145,544.00 |
| Jun 30, 2024 | 145,544.00 |
| Mar 31, 2024 | -45,269.00 |
| Mar 31, 2024 | -45,269.00 |
| Dec 31, 2023 | -967,215.00 |
| Dec 31, 2023 | -967,215.00 |